Kinesiophobia, adherence to treatment, pain and quality of life in fibromyalgia syndrome patients

Lorente, Giovana Davi; Stefani, Lia Fernanda Bocchi De; Martins, Marielza Regina Ismael

doi:10.5935/1806-0013.20140020

Acessibilidade / Reportar erro

Brasil

Español English

sumário « anterior atual seguinte »

Sumário

ORIGINAL ARTICLES • Rev. dor 15 (2) • Apr-Jun 2014 • https://doi.org/10.5935/1806-0013.20140020 copy

Kinesiophobia, adherence to treatment, pain and quality of life in fibromyalgia syndrome patients^* * Received from the School of Medicine of São José do Rio Preto, São José do Rio Preto, SP, Brazil.

Authorship SCIMAGO INSTITUTIONS RANKINGS

BACKGROUND AND OBJECTIVES:

Fibromyalgia syndrome is characterized by diffuse and chronic musculoskeletal pain, which is difficult to handle and negatively affects patients' quality of life. This study aimed at measuring fear of movement, adherence to treatment and at evaluating health-related quality of life of fibromyalgia syndrome patients.

METHODS:

This is a prospective study in convenience sample made up of individuals with fibromyalgia syndrome and treated in a Pain Outpatient Clinic. Tools used were: identification protocol, Fibromyalgia Impact Questionnaire, generic quality of life questionnaire World Health Organization's Quality of Life Instrument, visual analog scale, Tampa Scale for Kinesiophobia and treatment adherence measurement. Participated in the study 65 individuals being 35 with fibromyalgia syndrome called test group and 30 without diagnostic of musculoskeletal and neurological systems diseases called control group.

RESULTS:

The test group had predominance of females, mean age of 42.5±4.3 years, 53% were married and mean education was 9±2.5 years. Mean pain duration was 3.5±1.2 years and mean of two years for fibromyalgia syndrome diagnostic. There has been poorer quality of life, more severe pain and acknowledgment of the importance of physical activities, in spite of referring fear. In addition, adherence to pharmacological treatment was lower than that observed in the control group.

CONCLUSION:

Fibromyalgia patients had more severe pain, more fear of movement and poorer quality of life in physical an social domains. Adherence to treatment level was medium and there has been decreased functional capacity.

Evaluation; Fibromyalgia; Quality of life

Variables	Groups	n	Mean±SD	%	p value
Age (years)	Test	35	42.5±4.3		0.06
	Control	30	45.5±2.5
Gender	Test	35		Female 93	0.06
	Control	30		Female 80
Marital status	Test	35		Single 6.7
				Married 53.3
				Divorced 40
	Control	30		Single 6.7	0.08
				Married 58
				Divorced 28.6
				Widower 6.7
Pain duration (years)	Test	35	3.5 ±1.2		0.06
	Control	30	2.8± 1.8
Education (years)	Test	35	9 ±2.5		0.06
	Control	30	8 ±3.2
Labor situation	Test	35		Active 33.3
				Unemployed 0
				Retirement 6.7
				Benefit 60	0.06
				Active 37
	Control	30		Unemployed 11
				Rertirement 17
				Benefit 35
Weight (kg)	Test	35	67.14±9.49		0.58
	Control	30	68.5±8.13
Height (m)	Test	35	1.65±0.09		0.05
	Control	30	1.59±0.06

Variables	Test group Mean±SD	Control group Mean±SD	p value
Functional capacity	11.75±5.73	10.3±3.00	0.076
Feeling good	2.35±1.95	3.38±0.90	0.048^* * Descriptive significance level of 0.05 of Mann-Whitney non-parametric test.
Work absences	6.04±2.33	4.85±2.29	0.035^* * Descriptive significance level of 0.05 of Mann-Whitney non-parametric test.
Ability to work	7.14±2.05	6.76±2.00	0.065
Pain	8.11±2.67	5.41±3.19	0.035^* * Descriptive significance level of 0.05 of Mann-Whitney non-parametric test.
Fatigue	8.53±1.85	5.75±2.03	0.048^* * Descriptive significance level of 0.05 of Mann-Whitney non-parametric test.
Sleep	7.56±1.50	6.58±2.00	0.042^* * Descriptive significance level of 0.05 of Mann-Whitney non-parametric test.
Morning stiffness	8.59±1.04	6.56±3.19	0.003^* * Descriptive significance level of 0.05 of Mann-Whitney non-parametric test.
Anxiety	6.59±3.16	4.95±2.03	0.022^* * Descriptive significance level of 0.05 of Mann-Whitney non-parametric test.
Depression	6.41±2.50	5.35±2.29	0.012^* * Descriptive significance level of 0.05 of Mann-Whitney non-parametric test.

Domains	Test group (n=35) Mean±SD	Control group (n=30) Mean±SD	p value
Physical	49.8±12.8	64.5±12.5	0.048^* * Descriptive significance level of 0.05 of Mann-Whitney non-parametric test.
Psychological	59.6±20.7	68.6±18.9	0.119
Social	54.2±11.8	65.7±15.6	0.042^* * Descriptive significance level of 0.05 of Mann-Whitney non-parametric test.
Environmental	63.7±15.7	73.9±17.4	0.07
General	54.5±21.8	66.7±18.9	0.627

Adherence	Test group (n=35) Mean	Control group (n=30) Mean
High	20% (n=3)	35% (n=7)
Medium	60% (n=9)	50% (n=10)
Low	20% (n=3)	15% (n=3)

Sociedade Brasileira para o Estudo da Dor Av. Conselheiro Rodrigues Alves, 937 cj 2, 04014-012 São Paulo SP Brasil, Tel.: (55 11) 5904 3959, Fax: (55 11) 5904 2881 - São Paulo - SP - Brazil
E-mail: dor@dor.org.br

Acompanhe os números deste periódico no seu leitor de RSS

[1] Correspondence to: Marielza R. I. Martins, Av. Brigadeiro Faria Lima, 5416 - Departamento de Ciências Neurológicas, 15090-000 São José do Rio Preto, SP, Brasil. E-mail: marielzamartins@famerp.br

Brasil

Brasil

Kinesiophobia, adherence to treatment, pain and quality of life in fibromyalgia syndrome patients* * Received from the School of Medicine of São José do Rio Preto, São José do Rio Preto, SP, Brazil.

BACKGROUND AND OBJECTIVES:

METHODS:

RESULTS:

CONCLUSION:

Kinesiophobia, adherence to treatment, pain and quality of life in fibromyalgia syndrome patients^* * Received from the School of Medicine of São José do Rio Preto, São José do Rio Preto, SP, Brazil.